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background: Infants with congenital heart diseases (CHD) frequently lack sufficient myocardium and show scar formation. Therapies aimed at 
regenerating myocardium would change the way CHD is treated. We have shown that administration of recombinant neuregulin-1 (rNRG1) can 
stimulate heart muscle regeneration in adult mice following myocardial infarction. We hypothesized that the efficacy of rNRG1 therapy may be higher 
in the neonatal population and may provide a strategy to regenerate myocardium in infants with CHD.
methods: We developed a myocardial injury model (cryoinjury) in neonatal mice that recapitulates scar formation seen in infants with CHD and 
used it to evaluate the effectiveness of stimulating cardiomyocyte proliferation with rNRG1. We also evaluated the ability of rNRG1 to stimulate 
cardiomyocyte proliferation in cultured myocardium from infants with CHD.
results: (1) Administration of rNRG1 from four to 34 days after cryoinjury in neonatal mice resulted in a 2-fold increase in cardiomyocyte cell cycle 
activity at 10 days post injury (dpi), transiently reduced scar formation, and transiently improved myocardial structure and function. In contrast, 
administration of rNRG1 from birth to 30 days of life significantly improved the ejection fraction that was sustained up to 30 days after the cessation 
of rNRG1 administration. (2) rNRG1 induced cardiomyocyte proliferation in organotypic cultures of myocardium from infants with Tetralogy of Fallot 
(ToF). rNRG1-stimulated cardiomyocyte cell cycle activity decreased with infant age, with no proliferation occurring in patients older than 6 months.
conclusions: These results indicate a potential strategy for stimulating myocardial repair in human infants based on early administration of rNRG1 
to stimulate cardiomyocyte proliferation.
